Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: Relation with disease aggressiveness

Clinical and Experimental Rheumatology

Volumn 24, Issue 3, 2006, Pages 281-286

  del Val del Amo, Natividad ^a   Ibanez Bosch, Rosario ^a   Fito Manteca, Concepción ^a   Gutierrez Polo, Ricardo ^a   Loza Cortina, Eduardo ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Anti CCP antibody; Prognostic factor; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BONE EROSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; JOINTS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; QUESTIONNAIRES; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 33746594478     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. van GAALEN FA, van AKEN J, HUIZINGA TW et al.: Association between HLA class II genes and autoantibody to cyclic citrullinated peptides influences the severity of rheumatoid arthritis. Arthritis Rheum 2004; 20: 2113-21.
2. Van VENROOIJ WJ, PRUIJN GJ: Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000; 2: 249-51.
3. LOPEZ-HOYOS M, MARQUINA R, TAMAYO E et al.: Defects in the regulation of B cell apoptosis are required for the production of citrullinated peptide autoantibody in mice. Arthritis Rheum 2003; 48: 2353-61.
4. VOSSERNAAR ER, NIJENHUIS S, HELSEN MM et al.: Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2489-500.
5. ZHOU Z, MENARD HA: Autoantigenic post-translational modifications of proteins: does it apply to rheumatoid arthritis? Curr Opin Rheumatol 2002; 14: 250-3.
6. SUZUKI A, YAMADA R, CHANG X et al.: Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395-402.
7. SCHELLEKENS GA, de JUNG BA, van den HOOGEN KH, van de PUTTE LB, van VENROOIJ WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibody. J Clin Invest 1998; 101: 273-81.
8. SCHELLEKENS GA, VISSER H, DE JONG BA et al.: The diagnostic properties of rheumatoid arthritis antibody recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63.
9. JANSEN TL, BRUYN GA: Diagnostic value of anticyclic citrullinated peptide antibody in rheumatoid arthritis. J Rheumatol 2004; 31: 1012-3.
10. VOSSENAAR ER, van VENROOIJ WJ: Anti-CCP antibody, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004; 4: 259-62.
11. RANTAPAA-DAHLQVIST S, de JONG BA, BERGLIN E et al.: Antibody against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-9.
12. NIELEN MM, van SCHAARDENBURG D, REESINK HW et al.: Specific autoantibody precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6.
13. VISSER H, LE CESSIE S, VOS K, BREEDVELD FC, HAZES JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
14. NEWKIRK MM: Rheumatoid factors: what do they tell us?. J Rheumatol 2002; 29: 2034-40.
15. van GAALEN FA, LINN-RASKER SP, van VENROOIJ WJ et al.: Autoantibody to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-15.
16. HILL JA, SOUTHWOOD S, SETTE A, JEUNIKAR AM, BELL DA, CAIRNS E: Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1* 0401 MHC class II molecule. J Inmunol 2003; 171: 538-54.
17. GOLDBACH-MANSKY R, LEE J, McCOY A et al.: Rheumatoid arthritis associated autoantibody in patients with synovitis of recent onset. Arthritis Res 2000; 2: 236-43.
18. AHO K, PALOUSO T, HELIOVAARA M, KENKT P, ALHA P, von ESSEN R: Antifilaggrin antibody within "normal" range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000; 27: 2743-6.
19. KROOT EJ, de JONG BA, van LEEUWEN MA et al.: The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831-5.
20. BUKHARI M, HARRISON B, LUNT M, SCOTT DG, SYMMONS DP, SILMAN AJ: Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum 2001; 44: 1248-53.
21. BUKHARI M, LUNT M, HARRISON BJ, SCOTT DG, SYMMONS DP, SILMAN AJ: Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002; 46: 906-12.
22. van GERSTEL AM, PREVOO MLL, van't HOFMA et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996; 39: 34-40.
23. van der HEIJDE D, DANKERT T, NIEMAN F, RAU R, BOERS M: Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology 1999; 38: 941-47.
24. MIKULS TR, O'DELL JR, STONER JA et al.: Association of rheumatoid arthritis treatment respose and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004; 50: 3776-82.
25. BOBBIO-PALLAVICINI F, ALPINI C, CAPORALI R, AVALLE S, BUGATTI S, MONTECUCCO C: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6: R264-72.
26. VALLBRACHT I, RIEBER J, OPPERMANN M, FORGER F, SIEBERT U, HELMKE K: Diagnostic and clinical value of anti-cyclic citrullinated peptide antibody compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1079-84.
27. BERGLIN E, JOHANSSON T, SUNDIN U et al.: Radiological outcome in rheumatoid arthritis is predicted by the presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-rheumatoid factor at disease onset. Ann Rheum Dis. Published Online First: 21 September 2005; doi: 10.1136/ard.2005.041376.
28. BAS S, PERNEGER TV, SEITZ M, TIERCY JM, ROUX-LOMBARD P, GUERNE PA: Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibody, anti-keratin antibody and IgM rheumatoid factors. Rheumatology 2002; 41: 809-14.
29. JANSEN LM, van SCHAARDENBURG D, van der HORST-BRUINSMA I, Van der STADT RJ, de KONING MH, DIJKMANS BA: The predictive value of anti-cyclic citrullinated peptide antibody in early arthritis. J Rheumatol 2003; 30: 1691-5.
30. KASTBOM A, STRANDBERG G, LINDROOS A, SKOGH T: Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004; 63: 1085-9.
31. VENCOVSKY J, MACHACEK S, SEDOVA L et al.: Autoantibody can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 427-30.
32. MEYER O, LABARRE C, DOUGADOS M et al.: Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-6.
33. LINDQVIST E, EBERHARDT K, BENDTZEN K, HEINEGARD D, SAXNE T: Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 196-201.
34. LARSEN A: The relation of radiographic changes to serum acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17: 123-9.
35. AOTSUKA S, OKAWA-TAKATSUJI M, NAGATANI K et al.: A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 475-81.
36. GREINER A, PLISCHKE H, KELLNER H, GRUBER R: Association of anti-cyclic citrullinated peptide antibodies, anti-citrillin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1050: 295-03.
37. HUSTED JA, GLADMAN D, COOK RJ, FAREWEL VT: Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998; 25: 2146-55